IMO the number of outstanding shares is not that significant for a company like GNBT. The real issue is the low SP exacerbates the problem with share dilution. Also, I believe revenue is starting to come in based on a decrease in the rate of dilution over the past year (specifically this summer). Maybe coming in from Excellagen sales? No one really knows ... but we are all trying to read the tea leaves ...
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links